Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California. Show more

Location: 3800 Bridge Parkway, Redwood City, CA, 94065, United States | Website: https://seer.bio | Industry: Biotechnology | Sector: Healthcare


Market Cap

105.9M

52 Wk Range

$1.62 - $2.59

Previous Close

$1.88

Open

$1.89

Volume

181,583

Day Range

$1.84 - $1.93

Enterprise Value

-70.1M

Cash

199.2M

Avg Qtr Burn

-11.27M

Insider Ownership

3.35%

Institutional Own.

63.12%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date